About Broad Street Alerts: — ACAD Pipeline and Analyst Report
Big opportunities in Small Cap’s
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our
members in December 2015 alone.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100%
in gains for our members
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of
19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains
for our members.
***IN PLAY- Current profile sent at 3pm on March 24th, 2016 to our members up 17% so far (NASDAQ:
ICLD) full profile- https://broadstreetalerts.com/wp-content/uploads/2016/03/ICLD-profile.pdf
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your
ACAD Pipeline and Analyst Report
Trade-Ideas LLC identified ACADIA Pharmaceuticals ( ACAD) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified ACADIA Pharmaceuticals as such a stock due to the following factors:
- ACAD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $58.2 million.
- ACAD traded 581,527 shares today in the pre-market hours as of 8:53 AM, representing 23.8% of its average daily volume.
More details on ACAD:ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Currently there are 7 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.The average volume for ACADIA Pharmaceuticals has been 2.3 million shares per day over the past 30 days. ACADIA has a market cap of $2.6 billion and is part of the health care sector and drugs industry. The stock has a beta of 3.17 and a short float of 24.1% with 7.00 days to cover. Shares are down 43.2% year-to-date as of the close of trading on Wednesday.
Source: The Street
SCS LLC has not been compensated for this article.
SCS LLC was previously compensated up to twenty thousand dollars each by star media llc for the mention of INVT and XXII however those contracts have expired.